Prognostic significance of risk factors for thyrotoxicosis development in radioiodine therapy

Main Article Content

N.B. Ubaydullaeva
G.I. Allayarova
F.F. Almuradov

Abstract

Background. Graves’ disease (GD) is a systemic autoimmune disease that develops as a result of the production of antibodies to the thyroid-stimulating hormone receptor, which is clinically manifested by diffuse structural changes in the thyroid gland with the development of thyrotoxicosis syndrome, and also combined with extrathyroid manifestations. The purpose of the study was to identify Graves’ disease recurrence risk factors in women received radioiodine therapy. Materials and methods. 93 women of reproductive age who received radioiodine therapy (RIT) were under obsewrvation. We analyzed the results of the questionnaire and assessed the thyrotoxicosis recurrence risk factors with performed retrospective and prospective analysis of clinical and medical history indicators. Patient’s average age was 36.9 ± 7.1 years. The control group included 35 healthy women aged 33.5 ± 7.6 years. Thyroid stimulating hormone (TSH), free triiodothyonine (fT3) and free thyroxine (fT4) and thyroperoxidase antibodies (TPOAb) levels determined by the immunochemiluminescent method. Results. In order to evaluate the quality of a prognostic model of the thyrotoxicosis recurrence we calculated all risk factors parameters of the AUC. The most significant risk factors for the development of thyrotoxicosis recurrence after RTI with a high relative risk and etiological fraction were age over 30 years (RR = 7.59; EF = 8.82 %), thyroid volume ≥ 30 cm3 (RR = 6.84; EF = 85.38 %), treatment duration ≥ 2 years (RR = 6.37; EF = 84.30 %), patient compliance (RR = 6.19; EF = 83.84 %), RIT multiplicity (RR = 5.74; EF = 82.58 %) and a dose of RIT 300 MBq (RR = 5.41; EF = 81.52 %). Conclusions. It was revealed that the age is older than 30 years (AUC — 0.88), thyroid volume ≥ 30 cm3 (AUC — 0.86), treatment duration ≥ 2 years (AUC – 0.86), patient compliance (AUC — 0.85), RIT multiplicity (AUC — 0.85) and the dose of RIT (AUC — 0.82) have excellent predictive power.

Article Details

How to Cite
Ubaydullaeva, N., G. Allayarova, and F. Almuradov. “Prognostic Significance of Risk Factors for Thyrotoxicosis Development in radioiodine Therapy”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 6, Oct. 2020, pp. 502-6, doi:10.22141/2224-0721.16.6.2020.215390.
Section
Original Researches

References

Prasek K, Płazińska MT, Królicki L. Diagnosis and treatment of Graves' disease with particular emphasis on appropriate techniques in nuclear medicine. General state of knowledge. Nucl Med Rev Cent East Eur. 2015;18(2):110-6. doi:10.5603/NMR.2015.0026.

Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves' disease: a 10-year Australian cohort study. BMC Endocr Disord. 2018 Dec 12;18(1):94. doi:10.1186/s12902-018-0322-7.

Langenstein C, Schork D, Badenhoop K, Herrmann E. Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers. Rev Endocr Metab Disord. 2016 Dec;17(4):571-581. doi:10.1007/s11154-016-9386-8.

Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev. 2016 Feb 18;2:CD010094. doi:10.1002/14651858.CD010094.pub2.

Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016 Aug;89(1064):20160418. doi:10.1259/bjr.20160418.

El-Kareem MA, Derwish WA, Moustafa HM. Response rate and factors affecting the outcome of a fixed dose of RAI-131 therapy in Graves' disease: a 10-year Egyptian experience. Nucl Med Commun. 2014 Sep;35(9):900-7. doi:10.1097/MNM.0000000000000152.

Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Dutta P, Bhansali A. Factors predicting treatment failure in patients treated with iodine-131 for graves' disease. World J Nucl Med. 2013 May;12(2):57-60. doi:10.4103/1450-1147.136693.

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421. doi:10.1089/thy.2016.0229.

Lewis A, Atkinson B, Bell P, et al. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J. 2013 May;82(2):85-8.

Xing YZ, Zhang K, Jin G. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment. Biosci Rep. 2020 Jan 31;40(1):BSR20191609. doi:10.1042/BSR20191609.

Liu M, Jing D, Hu J, Yin S. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves' disease. Am J Med Sci. 2014 Oct;348(4):288-93. doi:10.1097/MAJ.0000000000000288.